Trial Profile
A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel; Irinotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 31 Jan 2021 Primary endpoint (PFS) has been met.
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer
- 29 Nov 2020 Status changed from recruiting to completed.